HC Wainwright Reiterates “Buy” Rating for BriaCell Therapeutics (NASDAQ:BCTX)

HC Wainwright reissued their buy rating on shares of BriaCell Therapeutics (NASDAQ:BCTX) in a research note released on Tuesday morning,Benzinga reports. They currently have a $32.00 price objective on the stock.

BriaCell Therapeutics Stock Performance

Shares of BCTX stock opened at $6.03 on Tuesday. The stock has a fifty day simple moving average of $4.10 and a two-hundred day simple moving average of $7.66. BriaCell Therapeutics has a 52-week low of $3.00 and a 52-week high of $36.60. The firm has a market capitalization of $22.37 million, a PE ratio of -0.45 and a beta of 1.34.

BriaCell Therapeutics (NASDAQ:BCTX) last posted its quarterly earnings results on Monday, March 17th. The company reported ($2.33) EPS for the quarter, missing analysts’ consensus estimates of ($1.94) by ($0.39). On average, sell-side analysts forecast that BriaCell Therapeutics will post -2.45 EPS for the current fiscal year.

Institutional Investors Weigh In On BriaCell Therapeutics

A number of hedge funds have recently made changes to their positions in BCTX. Vontobel Holding Ltd. raised its holdings in shares of BriaCell Therapeutics by 37.5% during the 4th quarter. Vontobel Holding Ltd. now owns 110,000 shares of the company’s stock worth $62,000 after acquiring an additional 30,000 shares in the last quarter. Virtu Financial LLC purchased a new stake in BriaCell Therapeutics during the fourth quarter valued at approximately $27,000. Finally, Cantor Fitzgerald L. P. bought a new stake in shares of BriaCell Therapeutics in the 4th quarter valued at approximately $32,000. 15.42% of the stock is currently owned by hedge funds and other institutional investors.

BriaCell Therapeutics Company Profile

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.